Analysis of Oesophageal Neuroendocrine Tumour Outcomes Abstract #1500

Introduction: Oesophageal Neuroendocrine Tumours(NETs) are rare neoplasms accounting for <2% of Gastroenteropancreatic NET(GEP NETs).
Aim(s): To present our patients' group clinicopathological features, treatment and prognosis.
Materials and methods: Retrospective analysis from a GEP NET database of 1700 patients treated from October 2007 to November 2015.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas
Keywords: oesophageal nec

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1678 Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)
Introduction: GEJ-NEN is mostly poorly differentiated NEC with poor prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Panpan Zhang
Authors: Zhang P, Lu M, Shen L, Wang W, ...
#443 Neuroendocrine Carcinoma (NEC) and Composite Exocrine-Neuroendocrine Carcinoma (CENEC) of the Stomach: A Clinicopathological Review of 58 Cases
Introduction: NEC of the stomach is an uncommon tumor accounting for 0.5% of all gastric carcinomas and about 6% of gastric NETs. CENEC contain both areas of NEC and conventional carcinoma. The histological diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Vladimir Khomyakov
#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies
Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Andreas Krieg
Authors: Krieg A, Riemer J C, Dizdar L, Mersch S, ...
Keywords: GEP-NEC
#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy
Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Authors: Childs A, Kirkwood A, Lee A, Caplin M, ...
Keywords: chemotherapy, Ki-67
#862 The Role of Chromogranin A as a Predictor of Radiological Disease Progression in Midgut and Pancreatic Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is an established neuroendocrine biomarker. However, its role as a predictor of radiological disease progression in all neuroendocrine tumors (NETs) has not been recognised yet.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Roberta E Rossi
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.